Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Postoperative TAV16 ctDNA detects molecular residual disease and predicts relapse after pancreatic cancer resection

ESMO Congress 2026